Preparation and evaluation of 99mTc-labeled cyclic arginine-glycine-aspartate (RGD) peptide for integrin targeting

Applied Radiation and Isotopes

Volumn 68, Issue 10, 2010, Pages 1896-1902

  Lee, Dong Eun ^a   Hong, Young Don ^a   Choi, Kang Hyuk ^a   Lee, So Young ^a   Park, Pil Hoon ^a   Choi, Sun Ju ^a  

^a Korea Atomic Energy Research Institute   (South Korea)

Author keywords

99mTc; Cyclic RGD peptide; Integrin; N3S1; Tumor targeting

Indexed keywords

AMINO ACID SEQUENCE; ANGIOGENESIS; ASPARTATES; CHELATING LIGANDS; COORDINATION CHEMISTRY; COORDINATION CORES; COORDINATION SITES; IN-VIVO; INTEGRIN RECEPTORS; INTEGRINS; MODEL SYSTEM; RGD PEPTIDE; SOLID PHASE SYNTHESIS; SOLID-PHASE; SYNTHETIC ROUTES; TETRADENTATE; TETRADENTATE LIGANDS; TRIPEPTIDE; TUMOR IMAGING AGENTS; TUMOR TARGETING; TUMOR XENOGRAFTS;

AMINO ACIDS; BIOMOLECULES; FUNCTIONAL GROUPS; LIGANDS; ORGANIC ACIDS; PEPTIDES; TECHNETIUM; TUMORS;

CHELATION;

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; PROLYLGLYCYLCYSTEINE; TECHNETIUM 99M; TRIPEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CYCLIC ARGININE GLYCINE ASPARTIC ACID PEPTIDE; CYCLIC ARGININE-GLYCINE-ASPARTIC ACID PEPTIDE; CYCLOPEPTIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; TECHNETIUM COMPLEX;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN MCF 7; CHELATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT; ANIMAL; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASM; SYNTHESIS; TRANSPLANTATION; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; DRUG DELIVERY SYSTEMS; INTEGRINS; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; TECHNETIUM; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 77955275321     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2010.04.029     Document Type: Article

References (21)

1. Bakker W.H., Albert R., Bruns C., Breeman W.A.P., Hofland L.J., Marbach P., Pless J., Pralet D., Stolz B., Koper J.W., Lamberts S.W.J., Visser T.J., Kenning E.P. (111-In-DTPA-d-Phe1)-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991, 49:1583-1591.
2. 3 for angiogenesis. Science 1994, 264:569-571.
3. 3-integrin expression. J. Nucl. Med. 2004, 45(10):1776-1783.
4. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 2004, 31:11-19.
5. Cyr J.E., Pearson D.A., Wilson D.M., Nelson C.A., Guaraldi M., Azure M.T., Lister-James J., Dinkelborg L.M., Dean R.T. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J. Med. Chem. 2007, 50:1354-1364.
6. 3 expression. Nucl. Med. Biol. 2006, 33:945-952.
7. 3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 1999, 40(6):1061-1071.
8. Haubner R., Wester H.J., Burkhart F., Senekowisch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycolated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 2001, 42:326-336.
9. 3 expression. Nucl. Med. (Stuttg). 2004, 43(1):26-32.
10. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J. Nucl. Med. 2006, 47:2000-2007.
11. 99mTc-based radiopharmaceutical. Bioconjugate Chem. 2002, 13:1200-1210.
12. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 1999, 99:2235-2268.
13. 3 directed radiopharmaceuticals for tumor imaging. Drugs Future 2003, 28:551-564.
14. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Delivery Rev. 2008, 60:1347-1370.
15. Miao Y., Quinn T.P. Peptide-targeted radionuclide therapy for melanoma. Crit. Rev. Oncol. Hematol. 2008, 67:213-228.
16. Morrison M.S., Ricketts S.A., Barnett J., Cuthbertson A., Tessier J., Wedge S.R. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J. Nucl. Med. 2009, 50:116-122.
17. 99m: chemistry and initial biological studies. J. Med. Chem. 1996, 39:1361-1371.
18. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med. Chem. 2008, 51:7980-7990.
19. Temming K., Schiffelers R.M., Molema G., Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Update 2005, 8:381-402.
20. 18F-FRGD2. J. Nucl. Med. 2005, 47(1):113-121.
21. Zitzmann S., Ehemann V., Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res. 2002, 62:5139-5143.